The Hidden Disease of the Middle-Aged

Liver disease is on the rise among middle-aged Americans, but many don’t know they have it—or that they could develop it. The liver performs critical jobs, including cleaning toxins from the blood, storing energy and nutrients, digesting fats and processing medications, alcohol and food. But a host of ills and abuses can wreak havoc on the liver, from heavy drinking and infection with hepatitis B or C to a scourge known as fatty-liver disease linked to di

The Week in Review: September 22 – September 29, 2017

Friday, September 29, 2017 News Recap: Merck discontinues HCV programs. There were rumours, but now it’s official: Merck has announced that it will discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. In a statement the company said the decision was made based on a review of available Pha...

The Week in Review: August 11 – August 18, 2017

Friday, August 18, 2017 Canada Great news in Canada. Two new drug regimens have been approved:  Vosevi from Gilead is a pangenotypic for retreatment of those who have failed previous DAA therapy Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection. And MAVIRET from AbbVie is the first and only 8-week, pan-genotypic treatment for hepatit...

Direct-acting Antivirals Effective in Older Patients with Hepatitis C

Treatment of hepatitis C virus (HCV) with sofosbuvir-based direct acting antivirals (DAAs) was recently found as effective and well-tolerated in elderly patients as it was in younger patients in previous development trials. "Historically, older patients have been underrepresented in studies evaluating the efficacy and safety of HCV treatment due to poor tolerability and suboptimal response to interferon-based regimens," the researchers wrote. Satapathy

Hep C Treatments Can Cause Adverse Effects in Older Patients

SAN FRANCISCO — Direct-acting antiviral medications can be effective in older patients with hepatitis C, but adverse reactions are common and the adjustment of other medications is often required, new research suggests."We need more data about these new treatments in the elderly," said Berta Pernas, from Corunna University Hospital in Spain."I think we can treat these patients, but caution for interactions and adverse events is required," she said here at